Search Results for "CT P6 Celltrion"
Celltrion Inc. (biosimilars of blockbuster biologics), its Celltrion Healthcare division, and Hospira Inc. (specialty generic injectables) will collaborate on the manufacturing and supply of eight bio...
Celltrion, a Korean biotech, filed with the FDA for approval of Remsima®, a biosimilar to Janssen’s Remicade, which is indicated for autoimmune diseases. Remsima is the first monoclonal anti...
SEOUL, July 2 (Reuters) - Celltrion Inc said on Wednesday its top shareholder is no longer considering a sale of a stake in the biotechnology company.
Following a Japanese approval last week Celltrion and partner Nippon Kayaku have claimed the US as the next target market for their Remicade (infliximab) biosimilar.
Celltrion Inc. (KOSDAQ:068270) submitted an application to FDA for Remsima infliximab, a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ) and
South Korea’s Celltrion and Japanese partner Nippon Kayaku eye the U.S. for the next approval of their biosimilar of Johnson & Johnson’s Remicade.
Celltrion Inc. (KOSDAQ:068270) subsidiary Celltrion Healthcare Hungary Kft granted Mundipharma International Ltd. (Cambridge, U.K.) exclusive distribution rights to market Remsima infliximab in the U....
Celltrion has filed an application with the FDA for approval to market Remsima, its biosimilar version of Johnson & Johnson a -More-
Matching PubMed Articles